Minal Barve

Also affiliated with Sarah Cannon

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 5 papers. Top paper: “Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer”.

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0217

N/A

3.2DataRank · unranked

126 citations

Nataliya V. Uboha, Meredith S. Pelster, Tanios Bekaii‐Saab, Minal Barve, Joel Saltzman +12 more

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies

Journal of Hematology & Oncology(2025)10.1186/s13045-025-01753-8

N/A

0.436DataRank · unranked

14 citations

Minal Barve, Devalingam Mahalingam, Jay Parekh, Michael R. Kurman, James Strauss +10 more

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Haematologica(2024)10.3324/haematol.2024.285754

N/A

0.406DataRank · unranked

14 citations

Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda +30 more

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

Clinical and Translational Science(2024)10.1111/cts.13854

N/A

0.360DataRank · unranked

10 citations

Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve +16 more

Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0987

N/A

0.269DataRank · unranked

5 citations

Mohammed Milhem, Christopher Hoimes, Asim Amin, Cristopher Lao, Robert M. Conry +17 more